论文部分内容阅读
目的观察中重度慢性阻塞性肺疾病(COPD)稳定期患者沙美特罗替卡松吸入剂临床疗效。方法 52例中重度COPD稳定期患者随机分为2组,治疗组(n=26)吸入沙美特罗替卡松。对照组(n=26)为空白对照组.不吸入沙美特罗替卡松。观察2组用药3月后肺功能的变化,St George’s呼吸问卷(SGRQ)调查,通过6min步行试验(6MWT)观察运动耐力的变化以及急性加重的人次、住院人次。结果用药3月后治疗组FEV1、最大肺活量(FVC)及FEVl/FVC比对照组明显改善,2组比较差异有显著性(P<0.05),治疗组SGRQ评分减少,运动耐力(6MWT)增加,随访3个月治疗组急性加重人次明显减少,与对照组比较差异有显著性(P<0.05)。结论吸入沙美特罗替卡松吸入剂可以改善稳定期中重度COPD患者肺功能与运动耐力,减少急性加重的发作,不良反应少,值得临床进一步推广。
Objective To observe the clinical efficacy of salmeterol and timentasone inhalation in stable COPD patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods Fifty-two patients with moderate to severe COPD were randomly divided into two groups. The treatment group (n = 26) received salmeterol and fluticasone. The control group (n = 26) was a blank control group, and did not inhaled salmeterol / fluticasone. The changes of pulmonary function after 3 months of treatment and St George’s Respiratory Questionnaire (SGRQ) were observed in 2 groups. The changes of exercise endurance, acute exacerbations and inpatients were observed by 6MW walk test (6MWT). Results After 3 months of treatment, FEV1, FVC and FEVl / FVC of the treatment group were significantly improved compared with the control group, the difference was significant (P <0.05), the treatment group SGRQ score decreased, exercise tolerance (6MWT) increased, The 3-month follow-up of the acute exacerbation group significantly reduced the number of patients with the control group, the difference was significant (P <0.05). Conclusion Inhaled salmeterol and terbutaline may improve lung function and exercise endurance of patients with moderate-to-severe COPD and reduce the incidence of acute exacerbations, with fewer side effects. It is worth further promotion in clinic.